A COMPARATIVE CLINICAL STUDY ON EFFICACY OF BHAVITA AMALAKI CHOORNA AND SHUDDHA GUGGULU IN DYSLIPIDEMIA

Abstract

Background: Dyslipidemia, a lipoprotein metabolism disorder, contributes significantly to atherosclerosis leading to
cardiovascular diseases, the major cause of morbidity and mortality in both developed as well as developing countries.
This calls for an urgent interventional strategy. Dyslipidemia being a chronic condition has to be managed by easily
available, safe and effective medicines. Based on these facts, the present study was planned. Objectives: To evaluate and
compare the efficacy of Bhavita Amalaki Choorna and Shuddha Guggulu in the management of dyslipidemia. Materials
and Methods: In this interventional, active controlled, open labeled study, a total of 33 dyslipidemic subjects were
alternatively allocated to receive Bhavita Amalaki Choorna (BA; n=16) and Shuddha Guggulu Vati (SG; n=17) in a
dosage of 3grams twice daily with takra (buttermilk) as anupana half an hour before food for 3 months out of which a
total of 30 completed the study. The assessment criteria were recorded at baseline and after treatment; assessed for the
efficacy of the interventions. Results: BA elicited statistically significant results in HDL and SG elicited statistically
significant results in Total Cholesterol, LDL and Triglycerides. Both the drugs elicited significant results in various other
objective parameters. There were statistically significant differences found only in HDL between the group. Conclusion:
Both BA and SG can be effective prescriptions for the management of Dyslipidemia. Amalaki is having added benefit of
being cost effective and easily available in most parts of India. Thus BA can be preferred over SG.